PYXSNasdaqPharmaceutical PreparationsUS GAAP · USD

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates and related oncology therapeutics. The company’s work centers on advancing cancer drug candidates through preclinical and clinical development and, where applicable, partnering for development and commercialization in selected markets.

Kysy yhtiöstä
Liikevaihto13,9milj. USD
−14,2 %v/v
Liikevoitto (EBIT)−84,4milj. USD
+5,6 %v/v
EBIT-marginaali−609,2%
−55,1 %-yks.v/v
Nettotulos−79,6milj. USD
−3,0 %v/v
Vapaa kassavirta−63,5milj. USD
−9,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−150−100−50050milj. USD2020: EBIT −13 milj. USD20202021: EBIT −70 milj. USD20212022: EBIT −123 milj. USD20222023: EBIT −82 milj. USD20232024: 16 milj. USD2024: EBIT −89 milj. USD20242025: 14 milj. USD2025: EBIT −84 milj. USD202514−84
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Pyxis Oncology, Inc.

Liiketoiminta

Osuus liikevaihdosta
Oncology drug candidates0 %

Clinical and preclinical cancer therapeutics, including ADC-based programs.

Collaboration and milestone revenue100 %

Revenue from licensing, development milestones, and partner agreements.

Research and development services0 %

Internal and partnered R&D activities supporting pipeline advancement.

Tuotteet

Raportoitu · osuus liikevaihdosta
79,7%20,3%FY2025100 %
  • Sale of Royalty Rights79,7 %
  • Milestone Revenue20,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Pyxis Oncology’s direct commercial customers are limited because its product candidates are still in development. Its economic counterparties are primarily pharmaceutical partners, research collaborators, and, if products are approved, healthcare providers, payors, wholesalers, and distributors in oncology markets. The company’s current revenue is tied to collaboration milestones rather than product sales.

Pharmaceutical collaboration partners

Partners such as Simcere that pay milestones and support development/commercialization in defined territories.

Healthcare providers and oncologists

Physicians who would prescribe approved oncology products and influence adoption.

Third-party payors

Insurers and reimbursement bodies that determine patient access and pricing economics.

Wholesalers and distributors

Channel partners that would handle product distribution if the company commercializes indirectly.

Research institutions and CROs

Clinical trial sites and contract research organizations that execute development work.

Strategia

The company’s strategy is centered on advancing oncology candidates through research, preclinical work, and clinical trials while protecting and expanding its intellectual property. It also uses partnering and out-licensing to create development optionality and, where possible, monetize milestones and future commercial rights in specific territories.

Advance the oncology pipelineKeskipitkä aikaväli

Clinical progress is the main driver of value creation for a development-stage biotech.

Partner for selected geographiesKeskipitkä aikaväli

Out-licensing can reduce commercialization burden and provide milestone economics.

Protect intellectual propertyPitkä aikaväli

Patent and know-how protection support exclusivity and partnering leverage.

Prepare for future commercializationKeskipitkä aikaväli

Approved products require sales, marketing, and distribution capabilities or partners.

Maantiede

Pyxis Oncology is headquartered in the United States and conducts its core corporate and development activities from there. Its disclosed commercial collaboration activity includes China, where a milestone was recognized from the regulatory approval of Suvemcitug under an out-licensing agreement. As a clinical-stage oncology company, its geographic footprint is shaped more by trial, partner, and regulatory locations than by manufacturing or sales infrastructure.

Riskit

Pyxis Oncology faces the typical risks of a clinical-stage biotech: development failure, regulatory uncertainty, and the need for additional capital before product sales begin. Its reliance on collaborators, especially for commercialization and foreign-market execution, adds counterparty and control risk, while oncology competition and healthcare compliance requirements can materially affect future value.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Competitive pressure in oncology3Need for additional capital2Commercialization dependence on partners4Regulatory and healthcare compliance5Cybersecurity and data handling6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Pipeline value depends on successful preclinical and clinical outcomes, which are uncertain.

    Kohdistuu: All product candidates

  2. Need for additional capitalVaikutus: KorkeaTodennäköisyys: Korkea

    The company has no approved products and continues to fund R&D and trials.

    Kohdistuu: Corporate funding and pipeline execution

  3. Competitive pressure in oncologyVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Many ADC and immunotherapy programs compete for the same indications and capital.

    Kohdistuu: Pipeline differentiation and partnering leverage

  4. Commercialization dependence on partnersVaikutus: KorkeaTodennäköisyys: Matala

    If it outsources sales or relies on collaborators, execution and economics are partly outside its control.

    Kohdistuu: Future approved products and ex-U.S. markets

  5. Regulatory and healthcare complianceVaikutus: KorkeaTodennäköisyys: Matala

    Drug promotion, pricing, and relationships with providers/payors are governed by strict laws.

    Kohdistuu: U.S. and international commercialization

  6. Cybersecurity and data handlingVaikutus: KeskitasoTodennäköisyys: Matala

    Clinical, proprietary, and personal data are stored across internal and third-party systems.

    Kohdistuu: R&D operations and collaborator networks

Kysy Clarifolta: Pyxis Oncology, Inc.

Kirjanpito

Harkinnanvaraiset erät
Milestone and collaboration revenue recognition

Revenue depends on achieving regulatory or contractual milestones, which can create volatile timing.

Vaikutus: Quarterly revenue can swing materially based on partner events

Research and development expense

Clinical and preclinical spending is the core cost base and is expensed as incurred.

Vaikutus: Directly drives operating losses and cash burn

Stock-based compensation

Biotech companies often use equity awards to retain talent, affecting operating expenses.

Vaikutus: Can materially increase reported G&A and R&D expense

Intangible assets and contract rights

Settlement or licensing transactions can require write-offs or fair-value adjustments.

Vaikutus: May affect cost of revenues and non-cash charges

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Precigen, Inc

PGEN · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

PDS Biotechnology Corp

PDSB · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Pyxis Oncology, Inc. (PYXS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo